Intensity Therapeutics Gets FDA Green Light for Phase 3 Study
January 03 2024 - 8:52AM
Dow Jones News
By Colin Kellaher
Intensity Therapeutics has received U.S. Food and Drug
Administration approval to launch a Phase 3 study of its lead drug
candidate INT230-6 in soft tissue sarcoma.
The Shelton, Conn., clinical-stage biotechnology company on
Wednesday said it is working with its contracted vendors to
initiate the study in the first half of the year.
Intensity said it plans to study INT230-6 as monotherapy
compared to standard-of-care drugs in second- and third-line
treatment for certain subtypes of soft tissue sarcoma, which are
cancers that start in soft tissues and are found mostly in the
arms, legs, chest and abdomen.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 03, 2024 08:37 ET (13:37 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.